Development of hyperdiploidy starts at an early age and takes a decade to complete
- PMID: 39571146
- DOI: 10.1182/blood.2024025250
Development of hyperdiploidy starts at an early age and takes a decade to complete
Abstract
Nearly half of patients with multiple myeloma (MM) have hyperdiploidy (HMM) at diagnosis. Although HMM occurs early, the mutational processes before and after hyperdiploidy are still unclear. Here, we used 72 whole-genome sequencing samples from patients with HMM and identified pre- and post-HMM mutations to define the chronology of the development of hyperdiploidy. An MM cell accumulated a median of 0.56 mutations per megabase before HMM, and for every clonal pre-HMM mutation, 1.21 mutations per megabase accumulated after HMM. This analysis using mutations before and after hyperdiploidy shows that hyperdiploidy happens after somatic hypermutation. Prehyperdiploidy mutations are activation-induced cytidine deaminase and age/clock-like signature driven, whereas posthyperdiploidy mutations are from DNA damage and APOBEC. Interestingly, the first hyperdiploidy event occurred within the first 3 decades of life and took a decade to complete. Copy number changes affecting chromosomes 15 and 19 occurred first. Finally, mutations before initiating event affected chromosomes at different rates, whereas post-initiating event mutational processes affect each chromosome equally.
© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Conflict-of-interest disclosure: K.C.A. has received consulting fees from Pfizer, Amgen, AstraZeneca, Janssen, and Precision Biosciences and serves on the board of directors of C4 Therapeutics, OncoPep, Mana, Raqia, NextRNA, Window, and Starton. N.C.M. is a consultant for Bristol Myers Squibb, Janssen, OncoPep, Amgen, Pfizer, Karyopharm, Legend, NextRNA, Raqia, AbbVie, Takeda, and Glaxo Smith Kline and serves on the board of directors of OncoPep. G.P. is a cofounder of Phaeno Biotech; serves on the scientific advisory board of Konica Minolta Healthcare Americas; and consults with Foundation Medicine and Delfi Diagnostics. M.K.S. is a consultant to AbbVie and K36 and is on the advisory board of Neuberg Center for Genomic Medicine. P.S. is on the advisory board of Neuberg Center for Genomic Medicine. The remaining authors declare no competing financial interests.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
